Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2017

View Archived Issues

DelSiTech and C-TRI to jointly develop long-acting controlled release formulations

Bioharmony Therapeutics receives support to develop lysins for bacterial infections

BeiGene begins phase II study of pamiparib

Twin epigenetic study reveals idiopathic epilepsy biomarkers

Array BioPharma and Pfizer to jointly test several cancer drug combinations

Shire reports topline results from phase II/III study of SHP-609

Pilot clinical study of Aclaris Therapeutics' ATI-50002 in vitiligo begins

REGENXBIO's IND for study of RGX-121 in MPS II now active

Elacestrant significantly reduced FES uptake in patients with ER+/HER2- breast cancer

Bispecific antibody targeting [90Y]-DOTA and CD45 may enhance radiotherapy for leukemia

Critical Outcome Technologies' COTI-2 safe, well tolerated in phase I study

FDA gives fast track designation to Ovid Therapeutics' OV-101 for Angelman syndrome

Novel P2X3 and/or P2X2/3 receptor antagonists identified at Shionogi

First patient screened in Minerva Neurosciences' phase III study of MIN-101

GlycoMimetics patents novel E-selectin binding inhibitors

BioMarin initiates first phase III study of valoctocogene roxaparvovec for severe hemophilia A

Transcriptx presents nucleic acids encodingdynein intermediate chain 1, axonemal

Updated phase II data for tetrathiomolybdate in patients with breast cancer at risk for recurrence

FDA approves Luxturna gene therapy for biallelic RPE65 mutation-associated retinal dystrophy

Faron Pharmaceuticals cleared to continue INFORAAA study of Traumakine

FDA approves Cabometyx for previously untreated advanced RCC

Second Genome's lead candidate demonstrates safety, tolerability in phase I study

Solid Biosciences initiates phase I/II study of SGT-001 in Duchenne muscular dystrophy

Otsuka and X-Chem sign collaborative research agreement

Onconova and HanX enter license and collaborative development agreement for ON-123300

FDA approves Prexxartan

Promising results for novel anti-EGFR radiotracer in patients with non-small cell lung cancer

FDA accepts for review BLA for Samsung Bioepis' trastuzumab biosimilar

FDA approves Bosulif for newly diagnosed Ph+ CML

Biogen and Ionis enter new collaboration for SMA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...